Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tandospirone SCHEMBL13532602 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL22693814 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL49026 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL22381099 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL16339864 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL1766255 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| SCHEMBL10925913 | 0.95 | DRD2 (0.90) | DRD2HTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL11011731 | 0.94 | DRD2 (0.91) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL15383602 | 0.92 | DRD2 (0.85) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL15383590 | 0.92 | DRD2 (0.84) | DRD2HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | claimed |
| US-20130267533-A1 | 5HT1A AGONISTS FOR TREATMENT OF HIGH CHOLESTEROL | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2013152108-A1 | 5HT1A AGONIST FOR TREATMENT OF HIGH CHOLESTEROL | FABRE, LOUIS, F. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2009137732-A1 | ADATANSERIN AND METABOLITES THEREOF FOR TREATMENT OF ATTENTION DEFICIT DISORDER, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, AND OTHER DISORDERS | FABRE KRAMER PHARMACEUTICALS, INC (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281112-A1 | ADATANSERIN AND METABOLITES THEREOF FOR TREATMENT OF ATTENTION DEFICIT DISORDER, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, AND OTHER DISORDERS | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2004002487-A1 | METHODS FOR TREATING ATTENTION DEFICIT DISORDER | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20040002500-A1 | Methods for treating attention deficit disorder | FABRE KRAMER PHARMACEUTICAL, INC. | 2004-01-01 | — | — | US | disclosed |
| US-5521313-A | REACTION OF SPIROQUATERNARY PIPERAZINIUM HYDROXIDE WITH IMIDE COMPOUND; HEATING | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
| US-5457120-A | Antisecretory and antiserotonine agents | ELI LILLY AND COMPANY (US) | 1995-10-10 | — | — | US | disclosed |
| US-4562255-A | HYPOTENSIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002500-A1 | Methods for treating attention deficit disorder | HTR5A, HTR2A, HTR2C | DRD2 37/4885HTR1A 4/4885DRD4 47/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | DRD2 242/4885HTR1A 7/4885DRD4 301/4885 |
| US-20090281112-A1 | ADATANSERIN AND METABOLITES THEREOF FOR TREATMENT OF ATTENTION DEFICIT DISORDER, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, AND OTHER DISORDERS | DRD2, DRD3, DRD4 | DRD2 1/4885HTR1A 18/4885DRD4 3/4885 |
| US-20130267533-A1 | 5HT1A AGONISTS FOR TREATMENT OF HIGH CHOLESTEROL | HTR1A, HTR3A, HTR2A | DRD2 189/4885HTR1A 1/4885DRD4 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.